Completed OBSERVATIONAL NCT01705132

Urinary Biomarkers of the Progression of Alport Kidney Disease

Sponsor: Novartis

Updated 11 times since 2017 Last updated: Jul 26, 2013 Started: Jun 30, 2012 Primary completion: May 31, 2013 Completion: Jul 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Alport Syndrome, this trial is completed. The trial is conducted by Novartis and has accumulated 11 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Dec 2021 — Jul 2024 [monthly]

Completed
Jan 2021 — Dec 2021 [monthly]

Completed
Nov 2020 — Jan 2021 [monthly]

Completed

▶ Show 6 earlier versions

Nov 2019 — Nov 2020 [monthly]

Completed
Jun 2018 — Nov 2019 [monthly]

Completed
May 2018 — Jun 2018 [monthly]

Completed
Apr 2018 — May 2018 [monthly]

Completed

Phase: NA → None
Aug 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Aug 2017 [monthly]

Completed NA

First recorded

Jun 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis
University of Minnesota

Data source: University of Minnesota

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Minneapolis, United States